{
    "2018-12-26": [
        [
            {
                "time": "",
                "original_text": "4+7带量采购价格战打响？恒瑞医药主动降价",
                "features": {
                    "keywords": [
                        "4+7",
                        "带量采购",
                        "价格战",
                        "恒瑞医药",
                        "降价"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "陆股通周报:北上资金减持大消费",
                "features": {
                    "keywords": [
                        "陆股通",
                        "北上资金",
                        "减持",
                        "大消费"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "消费"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "从美国仿制药企业兴衰看中外药企的估值差异和竞争策略:崛起和失落",
                "features": {
                    "keywords": [
                        "仿制药",
                        "估值差异",
                        "竞争策略",
                        "中美药企"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "理成资产CEO吴圣涛：价值投资者的黄金时段",
                "features": {
                    "keywords": [
                        "理成资产",
                        "吴圣涛",
                        "价值投资",
                        "黄金时段"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "235亿资金争夺20股：主力资金重点出击9股(名单)",
                "features": {
                    "keywords": [
                        "资金争夺",
                        "主力资金",
                        "重点出击",
                        "个股名单"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "今日两市超大账户减持的50只个股",
                "features": {
                    "keywords": [
                        "两市",
                        "超大账户",
                        "减持",
                        "个股"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：国家医保局开展DRGS国家试点申报工作推进医保支付方式改革",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "国家医保局",
                        "DRGS",
                        "医保支付改革"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗保健"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "看好中国｜健康中国——部分医药股仍具备中期投资价值",
                "features": {
                    "keywords": [
                        "健康中国",
                        "医药股",
                        "中期投资价值"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药：PD1单抗与阿帕替尼联合用药开展国际多中心临床",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "PD1单抗",
                        "阿帕替尼",
                        "联合用药",
                        "国际多中心临床"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "中国医药出海新突破 国产胰岛素类似物首次输出欧美",
                "features": {
                    "keywords": [
                        "中国医药",
                        "出海",
                        "胰岛素类似物",
                        "欧美市场"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "2018年A股牛股基因揭秘 229只逆势飘红股有三大特征",
                "features": {
                    "keywords": [
                        "A股",
                        "牛股",
                        "基因揭秘",
                        "逆势飘红",
                        "特征"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药:“SHR~1210+阿帕替尼”1b期数据优异，三期临床结果可期",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "SHR~1210",
                        "阿帕替尼",
                        "1b期数据",
                        "三期临床"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}